Inovio Pharmaceuticals, Inc. (AMEX:INO)
About Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals, Inc., formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (DNA) vaccines, focused on cancers and infectious diseases. The Companyâ€™s SynCon technology enables the design of universal DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses brief, controlled electrical pulses to increase
cellular DNA vaccine uptake. Inovio’s clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company’s HIV vaccines consist of candidates for HIV prevention as well as therapy or treatment.
52 week range
$0.76 - $1.55
Financials Inovio Pharmaceuticals, Inc. (AMEX:INO) generated total revenue of $1.28 million in current quarter which is barely greater than previous quarter’s revenue which was $1.13. Although Operating income is still negative but it describes better result than last period ended operating income. The company’s cash flow from operation stood at negative $8.59 million as contrasted to last quarter’s cash flow from operation which was placed at negative $7.81 million. According to most recent financials as on September 30, 2010 total assets mount up to $59.32 million. Return on equity and return on assets both are increasing. Total liabilities and total equity stand at $8.40 million, $50.92million respectively.
Protalix BioTherapeutics Inc. (AMEX:PLX)
About Protalix BioTherapeutics Inc. Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the ProCellEx protein expression system (ProCellEx). Using the ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on the plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. The ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. The ProCellEx protein expression system is built on bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures.
52 week range
$5.63 - $10.05
Financials Protalix BioTherapeutics Inc. (AMEX:PLX) generated total revenue of $3.18 million in existing quarter as on September 30th, 2010 which is considerably higher than last quarter ending revenue $1.14 million. However, total net income is still negative but has improved from last quarter. The companyâ€™s cash flow from operation stood at negative $30.43 million that explains dire indication as company could have face problems to repay it debts in future. Total current assets and current liabilities stood at $58.44 million and $20.49 respectively in present quarter which is a good sing as there would more net income and less interest payment in future.
Aoxing Pharmaceutical Company, Inc. (AMEX:AXN)
About Aoxing Pharmaceutical Company, Inc. Aoxing Pharmaceutical Company, Inc. (Aoxing Pharma), formerly China Aoxing Pharmaceutical Company, Inc., is a specialty pharmaceutical company located in the People’s Republic of China specializing in research, development, manufacturing and distribution of a range of narcotics and painmanagement products. The Company is working with the Chinese government and State Food and Drug Administration (SFDA) to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout the People’s Republic of China. The Company has one operating subsidiary, Hebei Aoxing Pharmaceutical Co., Inc. (Hebei Aoxing). Its product line is consisted of prescription and over-the-counter pharmaceutical products. Its pharmaceutical products have been approved by the SFDA, based on demonstrated safety and efficacy. It sells its products to hospitals, clinics, pharmacies and retail in most of the provinces of the People’s Republic of China.
52 week range
$1.52 - $4.16
Financials The Aoxing Pharmaceutical Company, Inc. (AMEX:AXN) reported increase in 12.25 percent in its total revenue for the quarter ended September 30 th, 2010. However, its operating income is still negative but depicts better result compared to last quarter ending. The company reported a considerable recovery in cash flow from operation which stood at negative $0.98 million compared to last ended quarter which was negative $3.98 million. The companyâ€™s total assets build up up to $58.99 million with greatest quantity of fixed assets in its composition. Return on equity and return on assets both are increasing. Total liabilities and total equity stand at $24.73 million, $34.27million respectively.
DISCLAIMER DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.
We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the â€œSECâ€?) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. ChartPoppers.com is a wholly-owned subsidiary of Seo Freisin, Inc.. While Seo Freisin has not been compensated for the distribution of this particular email, any future
email regarding a specific company will be the result of an advertising and promotional campaign for which Seo Freisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. Seo Freisin and its affiliates currently hold no shares in the profiled company.
Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).